Overview |
bs-9904R-APC-Cy7 |
IGFALS Polyclonal Antibody, APC-Cy7 Conjugated |
WB, IF(IHC-P) |
Human, Mouse, Rat |
Specifications |
APC-Cy7 |
Rabbit |
KLH conjugated synthetic peptide derived from human IGFALS/ALS |
251-350/605 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
3483 |
Albs; IGFALS; Insulin like growth factor binding protein acid labile subunit; Insulin like growth factor binding protein complex acid labile chain; MGC150140; MGC150141; KIAA4111; mKIAA4111; ALS_HUMAN. |
The Insulin-like growth factor binding proteins, or IGFBPs, are a family of seven proteins that have co-evolved with the IGFs. IGFBPs serve as shuttle molecules for both IGF-I and IGF-II and confer a level of regulation to the IGF signaling system by influencing the bio-availability, concentration and distribution of IGFs in the extracellular environment. In human circulation, the IGF-binging protein complex requires ALS (IGFBP acid-labile subunit), an extracellular protein involved in receptor-ligand binding and cell adhesion. ALS, detected primarily in plasma, is involved in protein-protein interactions that result in the formation of protein complexes. |
Application Dilution |
WB |
1:300-5000 |
IF(IHC-P) |
1:50-200 |